Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c

Praxis Precision Medicines (NASDAQ: PRAX) reported Q3 EPS of ($2.75), $0.76 worse than the analyst estimate of ($1.99). Revenue for the quarter came in at $302 thousand versus the consensus estimate of $328.56 thousand.

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Nomura/Instinet Upgrades MR DIY Group M Bhd (MRDIY:MK) to Buy
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)